Eggerthella lenta bacteremia successfully treated with ceftizoxime: case report and review of the literature

Eggerthella lenta was first described by Arnold Eggerth in 1935 [1], which was originally named Eubacterium lentum. E. lenta is a normal bacterium that can colonize the human gut, female reproductive tract, oral cavity, and prostate gland [2]. Due to the nature of strictly anaerobic and slow growth, E. lenta is difficult to culture and identify. Although, until recently, several microbial identification techniques, particularly mass spectrometry, were used to identify bacteria [3, 4], an increasing number of E. lenta infections in humans have been reported, referring to bloodstream infection [5‐7], liver abscess [8], bacterial vaginosis [9] and meningitis [10]. However, a unified standard treatment and its pathogenic mechanism have not yet been recognized. Here, we report cases of E. lenta bacteremia cured by ceftizoxime and review the existing recent literature. This article aims to add to existing data for the timely diagnosis and treatment of E. lenta bacteremia.

In recent years, Eggerthella lenta has received increasing attention as a human pathogen. However, due to its fastidious nature, some cases of E. lenta infection could previously have been undiagnosed by conventional biochemical methods [11]. Methods such as 16S ribosomal RNA (16S rRNA) gene sequencing techniques were considered the most accurate method. However, this method is costly and may not be readily available. Newer methods, such as MALDI-TOF MS, can quickly identify E. lenta and are more readily available at relatively low cost [4].

Several reports have shown that E. lenta can be isolated from humans at multiple sites [12‐15], which presented a greater challenge for its clinical diagnosis and treatment. Recent research has attempted to summarize the determinants of E. lenta bacteremia. An earlier study showed that most E. lenta bacteremia exhibited serious intra-abdominal pathology [16]. Our case, the patient admitted to the hospital due to appendicitis, was also consistent with this observation. E. lenta, which colonizes the intestinal tract, could easily invade the bloodstream through the damaged mucosa and cause bacteremia. However, other studies showed that patients with cancer, decubitus ulcers, and diabetes mellitus were more likely to suffer from E. lenta bacteremia [17, 18]. All of these investigations showed different results due to the different populations involved.

We summarized 175 patients with E. lenta bacteremia from the literature [5‐7, 10, 19‐31], along with the case reported here. The clinical characteristics of these 176 cases in total are presented in Table 1. Males (102/176) and individuals around 60 years of age (mean age = 61.2) were highly likely to be infected with E. lenta, while 63.3% had fever, 46.7% abdominal pain, 27.8% vomiting, and 16.1% diarrhea. This suggests that about 36.7% of the patients did not show fever symptoms in the case of E. lenta bacteremia, making it a great challenge for clinicians to accurately diagnose the bloodstream infection caused by this bacillus. Our data showed that the most common underlying health conditions for E. lenta bacteremia were solid or hematologic organ cancer (31.1%), diabetes mellitus (25.6%), and cardiovascular diseases (15.0%). These three conditions represented 71.7% of the total of 176 patients, while the main sources of infection in all of these patients were the gastrointestinal tract (65.0%), skin and soft tissues (19.4%), and abscess (8.9%). Of all initial symptoms, appendicitis accounts for the highest proportion, 21.8%, much higher than colitis, the second largest, 9.4%. Appendicitis is often accompanied by perforation or even peritonitis. E. lenta, normally colonized in the gastrointestinal tract, could invade the bloodstream more easily. Therefore, patients with tumors, diabetes mellitus, and appendicitis should pay more attention to bloodstream infection by E. lenta.

The most efficient antibacterial drugs against E. lenta infection are metronidazole, amoxicillin–clavulanate, and carbapenems; it is resistant to ceftriaxone [7, 16, 18, 20, 32]. Our patients empirically used ceftizoxime without clear pathogenic bacteria and showed good efficacy, which to our knowledge, has not been reported so far in the literature. Although both ceftizoxime and cefotaxime belong to the third generation of cephalosporins, ceftizoxime has a higher antianaerobic activity than cefotaxime [33], which may be the reason why our patients have a better response to ceftizoxime. However, there could be other reasons. An earlier study divided 29 patients infected with E. lenta into two groups and found one susceptible to beta-lactam drugs, while the other was completely resistant to beta-lactam antibiotics [34]. From this, we could speculate that our strain belonged to the group that was sensitive to beta-lactam antibiotics. It was unfortunate that we were unable to perform antimicrobial susceptibility tests due to the limitations of our conditions. Although more tangible evidence is needed to confirm, our findings also contribute to a better understanding of the resistance characteristics of E. lenta.

To conclude, the frequency of E. lenta bacteremia is increased in patients with hematologic or solid organ cancer, diabetes mellitus and also in those with appendicitis. E. lenta bacteremia in our study was successfully treated with ceftizoxime; however, this needs to be further confirmed in future research.